294 related articles for article (PubMed ID: 23787063)
1. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Laurie SA; Hao D; Leighl NB; Goffin J; Khomani A; Gupta A; Addison CL; Bane A; Seely J; Filion ML; Pond GR; Levine MN
Lung Cancer; 2017 Feb; 104():65-69. PubMed ID: 28213002
[TBL] [Abstract][Full Text] [Related]
6. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS
Lancet Respir Med; 2019 Jul; 7(7):569-580. PubMed ID: 31103412
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
10. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
14. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
Ou SH; Moon J; Garland LL; Mack PC; Testa JR; Tsao AS; Wozniak AJ; Gandara DR
J Thorac Oncol; 2015 Feb; 10(2):387-91. PubMed ID: 25611229
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Fazio C; Annesi D; Lenoci M; Amato G; Danielli R; Altomonte M; Giannarelli D; Di Giacomo AM; Maio M
Lancet Respir Med; 2015 Apr; 3(4):301-9. PubMed ID: 25819643
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
[TBL] [Abstract][Full Text] [Related]
20. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
